Tempus AI Approaching Profitability Despite GAAP Losses

Tempus AI reported a profitability inflection with its first positive Adjusted EBITDA in Q3 2025, raised full-year revenue guidance and reaffirmed slightly positive adjusted EBITDA for full-year 2025, while guiding Q4 adjusted EBITDA to remain positive. Q3 gross profit nearly doubled year-over-year reflecting scale across Genomics and Data & services, though GAAP losses persist due to substantial stock-based compensation, higher amortization from the Ambry acquisition and a one-time debt extinguishment loss; the Paige acquisition also pressures near-term earnings. Shares have rallied ~81.4% over the past year and the stock trades at a premium forward 12-month P/S of 7.42x versus an industry 5.77x; Zacks notes estimates unchanged recently and assigns a Rank #3 (Hold).

Analysis

Market structure: TEM’s reported positive adjusted EBITDA and raised revenue guide most directly benefit Tempus (TEM), AI compute suppliers (NVDA, AMD), and customers needing scaled genomics/data services; incumbents with legacy diagnostics could be pressured on price. TEM trades at a rich forward P/S 7.42x after an 81.4% 12‑month rally, so further share gains require visible GAAP progress to justify multiple expansion.

Risk assessment: Key tail risks are regulatory setbacks on AI diagnostics, failed integration of Paige driving protracted amortization/SBC dilution, or a reversal in Data bookings conversion; each could cause >50% downside in adverse scenarios. Near-term (days–weeks) risk centers on Q4 guidance beats/misses and options vol; medium (3–12 months) hinges on ADLT migration conversion rates and compute spend; long-term (12–36 months) depends on GAAP profitability trajectory and regulatory approvals.

Trade implications: Tactical exposure should be small and hedged: favor a measured long TEM exposure to capture margin operating leverage but protect against GAAP-driven drawdowns; consider relative value vs consumer telehealth (HIMS) and overweight AI compute (NVDA). Entry within 2–6 weeks to capture Q4/ADLT updates; trim if TEM rallies >30% or GAAP guidance unchanged by Q2 2026.

Contrarian angles: Consensus focuses on adjusted EBITDA; it underweights recurring non‑cash charges (SBC, amortization) and one‑offs that keep GAAP losses. The market may be underpricing the probability of a regulatory or integration failure — position sizes should assume a 30–50% tail drawdown unless GAAP guidance improves, creating asymmetric risk/reward for hedged, time‑defined trades.

Key Decisions for Investors

• Establish a 1.5%–2.5% long position in TEM (ticker TEM) within 2–6 weeks; hedge with a 6‑month 10% OTM protective put sized to cover 50% of the holding; plan to hold 6–9 months to test Q4 ADLT conversion and any GAAP guidance changes; reduce to 0.75% if TEM rallies >30%.
• Implement a funded options LEAP strategy: buy a 12‑month TEM call ~30% OTM (size 0.5% portfolio risk) and finance by selling 3‑month calls 25% OTM; this captures upside while capping cost and forcing a re‑assessment at each quarterly roll.
• Execute a pair trade: long TEM 1.5% / short HIMS 1.5% to express AI‑data vs consumer telehealth exposure; unwind if TEM underperforms HIMS by 20% over 90 days or if HIMS posts sustainable positive net income expansion while TEM misses adjusted EBITDA guidance.
• Rotate 2% of portfolio from consumer telehealth exposure (HIMS) into AI compute/semiconductor exposure (NVDA) to capture the compute tail supporting TEM’s long‑term model; hold NVDA 6–12 months and reassess on data center spend reports.
• Monitor three hard triggers over next 30–90 days before increasing size: (a) Q4 adjusted EBITDA remains positive, (b) Data bookings conversion rate ≥60% quarter‑over‑quarter or book‑to‑bill shows backlog conversion, and (c) management issues GAAP net loss guidance narrowing toward breakeven by Q2 2026; if any trigger fails, cut TEM exposure by at least 50%.